Kenya

Sigma-Tau S.p.A. and Medicines for Malaria Venture (MMV) have completed development of Eurartesim a fixed-dose Artemisinin-based Combination Therapy (ACT) which contains dihydroartemisinin (a derivative of artemisinin) and piperaquine. Eurartesim is indicated for the treatment of uncomplicated Plasmodium falciparum malaria. The registration dossier has been submitted to EMA on July 2009. The registration is expected during Q4 2010. After that, dossiers will be submitted to the endemic countries.

Secure The Future is a comprehensive initiative to fight HIV/AIDS in sub-Saharan Africa, sponsored by Bristol-Myers Squibb and the Bristol-Myers Squibb Foundation. It combines medical treatment and care, access to antiretroviral medicines, with research, social support with community education, and training for health care professionals with new facilities and infrastructure investments in remote areas of sub-Saharan Africa where resources are extremely limited.

In 2002, Bayer HealthCare agreed to supply - at no cost and for an initial five-year period - as much of the sleeping sickness medicine Germanin (suramin) as the World Health Organization (WHO) determines is needed to eliminate the disease. The initial donation comprised 50,000 ampoules. Bayer is also in favor of supporting an 'Integrated Sleeping Sickness Initiative' fostered by a broad base of institutions and covering all aspects of the disease from infection, diagnosis and therapy to prevention.

The Abbott Fund is partnering with several organizations to expand access to health care for mothers and children affected by HIV/AIDS in developing countries. Since 2001, more than 1 million children and adults have received services in Burkina Faso, India, Kenya, Malawi, Romania, Tanzania and Uganda. The Abbott Fund supported the Baylor College of Medicine in establishing a pediatric HIV/AIDS treatment program in Romania that reduced the death rate for children with HIV in the program by more than 90%.